Cancer

Multiple Myeloma Study C16029

A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies

Trial overview

Disease

Myeloma

Topic

Multiple Myeloma Study C16029

Sponsor

Description

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM)

Trial status

Recruitment closed

Location

Principle Investigator

Dr Karthik Ramasamy

MBBS, PhD, FRCP, FRCPath

Haematologist

Oxford